Laboratory operator Quest Diagnostics raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests, after posting strong results for the third ...

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...

Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for ...

Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in ...

Epic will partner with Quest on Project Nova, a multi-year effort to streamline and enhance customer-facing processes for patients and providers across all EHR platforms. The implementation will ...

Quest Diagnostics DGX is set to release its third-quarter 2025 results on Oct. 21, before the market opens. The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.62 in the ...

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

The Elecsys pTau181 test is the second blood test cleared by the FDA this year for use in Alzheimer’s evaluation. In May, the ...

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP ...

Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter. The provider of diagnostic ...